Trump has reversed some of President Biden’s initiatives, including $2 monthly out-of-pocket cap on some generics and experimental pricing models for gene therapies. But so far the healthcare elements of the Inflation Reduction Act remain unchanged.

The Trump administration’s first drug pricing action — rescinding a Biden executive order encouraging Medicare to help lower prescription costs — is befuddling drug pricing experts.

Only Congress can repeal parts of the Inflation Reduction Act that now lets Medicare negotiate drug prices. Still, some are worried cuts could come that hurt seniors and people wi